{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Infusion&page=5", "query": { "intervention": "Infusion", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 13275, "total_pages": 1328, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Infusion&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Infusion&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T22:16:15.365Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03872947", "title": "A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Colorectal Cancer", "Cholangiocarcinoma", "Bladder Cancer", "Ovarian Cancer", "Gastric Cancer", "Palpable Subcutaneous Malignant Lesions", "Renal Cell Carcinoma", "Melanoma", "Epithelial Ovarian Cancer", "Primary Peritoneal Cancer", "Fallopian Tube Cancer" ], "interventions": [ { "name": "TRK-950", "type": "BIOLOGICAL" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Imiquimod Cream", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "PLD", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Toray Industries, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 138, "start_date": "2019-04-26", "completion_date": "2026-07-16", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-29T22:16:15.365Z", "location_count": 13, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 10 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03872947" }, { "nct_id": "NCT01746238", "title": "Bevacizumab/Doxorubicin/Radiation for Sarcoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2013-03", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-10-29T22:16:15.365Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01746238" }, { "nct_id": "NCT00850785", "title": "Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "DRibble vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2009-01", "completion_date": "2012-05", "has_results": false, "last_update_posted_date": "2016-09-27", "last_synced_at": "2026-10-29T22:16:15.365Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00850785" }, { "nct_id": "NCT06402968", "title": "Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Intracerebral Hemorrhage", "Stroke", "Hypertension" ], "interventions": [ { "name": "Clevidipine Injection", "type": "DRUG" }, { "name": "Alternate IV Antihypertensive Regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zeenat Qureshi Stroke Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 1018, "start_date": "2024-06-01", "completion_date": "2028-07-30", "has_results": false, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-10-29T22:16:15.365Z", "location_count": 20, "location_summary": "Irvine, California • Lancaster, California • Palo Alto, California + 17 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Stuart", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06402968" }, { "nct_id": "NCT07630168", "title": "Effects of Infusion Timing on Treatment Response in Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer", "Non-small Cell Lung Cancer", "Metastatic Lung Cancer", "Head and Neck Cancer", "Metastatic Squamous Cell Carcinoma", "Metastatic Head and Neck Cancer", "Resectable Head and Neck Squamous-cell Carcinoma" ], "interventions": [ { "name": "PD-1/PD-L1 inhibitor monotherapy - 4 cycles before 12:00PM", "type": "DRUG" }, { "name": "PD-1/PD-L1 inhibitor monotherapy - 4 cycles after 3 PM", "type": "DRUG" }, { "name": "PD-1 inhibitor monotherapy - 2 cycles before 12:00PM", "type": "DRUG" }, { "name": "PD-1 inhibitor monotherapy - 2 cycles after 3 PM", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 238, "start_date": "2026-08-03", "completion_date": "2033-01-01", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-29T22:16:15.365Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07630168" }, { "nct_id": "NCT04376684", "title": "Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Severe Acute Respiratory Syndrome" ], "interventions": [ { "name": "Otilimab", "type": "BIOLOGICAL" }, { "name": "Placebo 1", "type": "BIOLOGICAL" }, { "name": "Placebo 2", "type": "BIOLOGICAL" }, { "name": "Standard of care", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1156, "start_date": "2020-05-28", "completion_date": "2021-08-16", "has_results": true, "last_update_posted_date": "2024-09-23", "last_synced_at": "2026-10-29T22:16:15.365Z", "location_count": 21, "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Sacramento, California + 18 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Sacramento", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04376684" }, { "nct_id": "NCT04731233", "title": "Efficacy of PRGF Supplementation After TMJ Arthrocentesis in Patients With TMJ Osteoarthritis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "TMJ", "Osteoarthritis" ], "interventions": [ { "name": "Plasma Rich in Growth Factor (PRGF) Supplementation", "type": "BIOLOGICAL" }, { "name": "Triamcinolone Acetonide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "FEMALE", "summary": "40 Years to 80 Years · Female only" }, "enrollment_count": 5, "start_date": "2021-03-30", "completion_date": "2024-02-21", "has_results": true, "last_update_posted_date": "2025-02-21", "last_synced_at": "2026-10-29T22:16:15.365Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04731233" }, { "nct_id": "NCT07587047", "title": "Adia Med of Winter Park LLC Lower Back Pain Research Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Mechanical Lower Back Pain", "Lower Back Pain", "Chronic Lower Back Pain" ], "interventions": [ { "name": "Umbilical Cord Blood-Derived Stem Cells and Exosomes", "type": "BIOLOGICAL" }, { "name": "Placebo IV", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Adia Med of Winter Park LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 100, "start_date": "2026-06-16", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-29T22:16:15.365Z", "location_count": 1, "location_summary": "Winter Park, Florida", "locations": [ { "city": "Winter Park", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07587047" }, { "nct_id": "NCT06663358", "title": "A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Fabry Disease" ], "interventions": [ { "name": "Pegunigalsidase-alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Chiesi Farmaceutici S.p.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2024-11-06", "completion_date": "2029-11", "has_results": false, "last_update_posted_date": "2025-11-14", "last_synced_at": "2026-10-29T22:16:15.365Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06663358" }, { "nct_id": "NCT02005315", "title": "A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer", "Stage IV Pancreatic Cancer" ], "interventions": [ { "name": "Vantictumab", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoMed Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 30, "start_date": "2013-09", "completion_date": "2017-11", "has_results": false, "last_update_posted_date": "2020-09-09", "last_synced_at": "2026-10-29T22:16:15.365Z", "location_count": 5, "location_summary": "Los Angeles, California • Aurora, Colorado • Indianapolis, Indiana + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02005315" } ] }